Regenerative and biologic therapy¶
TL;DR — Disc regeneration must solve cell survival, matrix restoration, annular containment, endplate transport, mechanical integration and clinically meaningful pain/function—not merely change MRI signal. Randomized cell trials now provide proof-of-concept signals: allogeneic disc progenitor cells increased disc volume and improved clinical outcomes in one FDA-authorized trial, while mesenchymal-stromal-cell trials have produced mixed results across products and populations (Gornet 2024, PMID 38925869; Noriega 2017, PMID 27661661; Pers 2024, PMID 39393844). Product heterogeneity, small samples, selective reporting and limited long-term safety keep cells, PRP, gene therapy and hydrogels investigational (Schneider 2022, PMID 34352363).
What “regeneration” must mean¶
| Domain | Candidate endpoint | Why insufficient alone |
|---|---|---|
| Composition | T1ρ/T2/sodium change | Scanner and surrogate uncertainty |
| Structure | Disc volume/height | May not restore mechanics or pain |
| Matrix | Proteoglycan/collagen | Usually inaccessible in humans |
| Mechanics | Pressure/stiffness/range | Measurement difficult in vivo |
| Symptoms | Pain reduction | Expectancy and nonspecific effects |
| Function | ODI/participation | Can improve without regeneration |
| Durability | Years without reintervention | Long follow-up required |
| Safety | No infection/tumor/ectopic tissue | Rare harms need large registries |
A regenerative claim should require concordant structural/biological and clinical evidence with durability.
Biological constraints¶
The disc is avascular, hypoxic, acidic, nutrient-limited and mechanically loaded. Injected cells face low glucose, high osmolarity, inflammatory mediators and expulsion through the needle tract (Urban 2007, PMID 17260404; Kadow 2015, PMID 25024024).
| Barrier | Consequence | Design response |
|---|---|---|
| Poor endplate transport | Cell death/low synthesis | Select earlier disease; address transport |
| Acidic pH | Reduced viability | Precondition/select tolerant cells |
| High pressure | Leakage and cell stress | Volume and delivery control |
| Annular fissure | Product extrusion | Carrier/closure strategy |
| Inflammation | Catabolic phenotype | Immunomodulation |
| Advanced collapse | Insufficient scaffold/space | Exclude late-stage disease |
| Abnormal mechanics | Reinjury of new matrix | Mechanical rehabilitation/repair |
Cell sources¶
| Product | Proposed advantage | Principal uncertainty |
|---|---|---|
| Autologous bone-marrow MSC | Familiar source | Age/comorbidity and batch variability |
| Allogeneic MSC/precursor | Scalable standardized manufacture | Immune/potency variability |
| Adipose-derived MSC | Accessible yield | Phenotype and safety |
| Disc progenitor cells | Disc-adapted potential | Manufacture, identity, persistence |
| Native NP cells | Tissue phenotype | Harvest and expansion |
| iPSC-derived cells | Scalable developmental phenotype | Tumorigenicity and control |
| Notochordal-cell products | Trophic signaling | Human source and product definition |
“MSC” is not one intervention. Source, expansion, passage, dose, viability, carrier and potency assay must be reported.
Randomized cell trials¶
| Trial/publication | Product/population | Signal | Key limitation |
|---|---|---|---|
| Noriega 2017 | Allogeneic marrow cells | Clinical/imaging improvement in small RCT | Small sample (PMID 27661661) |
| Amirdelfan 2021 | Allogeneic mesenchymal precursor cells | 36-month safety/efficacy signal | Product-specific, sponsor context (PMID 33045417) |
| RESPINE 2024 | Allogeneic marrow MSC | Placebo-controlled multicenter trial | Mixed/endpoint interpretation (PMID 39393844) |
| Disc progenitor 2024 | Allogeneic discogenic cells | Volume and clinical improvement | Replication and long-term safety (PMID 38925869) |
| DREAM 2025 | Intradiscal MSC, multilevel disease | Preliminary phase IIb report | Early report/small strata (PMID 40462867) |
| Mesenchymal precursor 2025 | MPC ± hyaluronic acid | 36-month randomized follow-up | Product and selection specificity (PMID 40174800) |
The studies cannot be pooled as a class effect without resolving product and phenotype heterogeneity.
Disc progenitor-cell trial¶
The FDA-authorized randomized trial reported that a high-dose allogeneic disc progenitor-cell product increased disc volume and improved pain, disability and quality of life (Gornet 2024, PMID 38925869).
Interpretation requires:
- prespecified primary endpoint and multiplicity review;
- participant and assessor blinding;
- dose–response consistency;
- handling of missing data;
- structural–clinical correlation;
- product manufacturing reproducibility;
- independent replication;
- tumor, ectopic tissue and immune surveillance.
An increase in volume is mechanistically interesting but not by itself proof of restored native biomechanics.
Mesenchymal stromal cells¶
MSC may act through paracrine immunomodulation more than durable engraftment. Reviews note that hostile disc conditions and uncertain cell fate challenge a simple replacement model (Vadalà 2021, PMID 34376495; Ekram 2021, PMID 35069988).
Early phase-I adipose-derived MSC plus hyaluronic acid work primarily established feasibility and tolerability, not comparative efficacy (Kumar 2017, PMID 29141662).
Systematic reviews report encouraging signals but judge certainty low because trials are few, small and heterogeneous (Schneider 2022, PMID 34352363; Manchikanti 2024, PMID 39688822).
Platelet-rich plasma and autologous concentrates¶
PRP delivers variable concentrations of platelets and growth factors; leukocyte content and activation differ. Bone-marrow concentrate contains mixed cells and soluble factors and is not equivalent to expanded MSC.
| Product | Evidence summary | Status |
|---|---|---|
| Intradiscal PRP | Small trials and heterogeneous reviews | Investigational (PMID 32607308) |
| PRP releasate vs steroid | Positive double-blind RCT signal | Needs replication (PMID 35053999) |
| Bone-marrow concentrate | Low-quality case series/cohorts | Investigational (PMID 32782864) |
| Autologous biologic combinations | Product-specific | Cannot infer class efficacy (PMID 39017984) |
Autologous origin reduces some immune issues but does not eliminate infection, contamination, dose or efficacy uncertainty.
Growth factors and small molecules¶
Candidate anabolic signals include BMPs, GDF-5/6, TGF-β-family factors, IGF-1 and connective-tissue regulators. Anti-catabolic candidates target IL-1, TNF, NF-κB, MAPK, aggrecanases and MMPs (Rider 2019, PMID 31435545; Zhang 2021, PMID 34536759).
Challenges are short half-life, off-target effects, osteogenesis, fibrosis and delivery through dense matrix. A growth factor that increases matrix in culture may cause ectopic bone or fail under load in vivo.
Gene and RNA therapy¶
Vectors or RNA systems could provide sustained anabolic, anti-inflammatory or senescence-modifying effects. Targets include matrix genes, IL-1 antagonism, transcription factors, microRNAs and noncoding RNAs (Wang 2015, PMID 26368266; Ran 2022, PMID 35653923).
| Platform | Advantage | Risk |
|---|---|---|
| Adenoviral | High expression | Immunogenic/transient |
| AAV | Longer expression | Packaging and irreversibility |
| Lentiviral | Stable integration | Insertional risk |
| mRNA | Non-integrating | Delivery and duration |
| miRNA mimic/inhibitor | Network modulation | Off-target network effects |
| CRISPR/editing | Precise target possibility | Off-target and permanent change |
A live PubMed E-utilities and ClinicalTrials.gov sweep on 2026-08-30 found gene/RNA delivery work in reviews and preclinical models but no human clinical gene- or RNA-transfer therapy for DDD; registered intradiscal rhGDF studies deliver recombinant protein, not a gene therapy.
Hydrogels and scaffolds¶
Hydrogels can carry cells/drugs, fill defects and modify mechanics. Desired properties conflict:
| Property | Need | Failure mode |
|---|---|---|
| Injectability | Minimally invasive delivery | Low viscosity/leakage |
| Rapid gelation | Retention | Needle blockage/inhomogeneity |
| Strength | Load support | Excess stiffness/endplate stress |
| Adhesion | Annular retention | Difficult deployment |
| Degradation | Tissue replacement | Too fast collapse/too slow persistence |
| Biocompatibility | Cell survival | Inflammation/toxic crosslinker |
| Imaging visibility | Monitor placement | Additive effects |
Hydrogel reviews show extensive preclinical innovation but sparse human evidence (Zhang 2025, PMID 41084298; Nie 2025, PMID 40727644).
Annular repair¶
Repairing nucleus without closing an annular defect risks extrusion. Annular devices, adhesives, sutures and fiber-reinforced scaffolds must withstand cyclic tension and torsion. Herniation-prevention devices answer a different question from whole-disc regeneration.
Outcome should include recurrent herniation, migration, endplate effects and MRI as well as pain.
Endplate strategy¶
Endplate sclerosis or defect can limit nutrient delivery and alter stress. Regeneration may fail if endplate transport is not adequate (Muftuler 2015, PMID 25421547).
Possible strategies—perfusion modification, microchannels, anti-sclerosis or endplate repair—remain preclinical and carry fracture/infection risk. Endplate phenotype should at least be measured in cell trials.
Preclinical models¶
| Model | Use | Translation limitation |
|---|---|---|
| Rodent tail puncture | Rapid screening | Different load/cell biology |
| Mouse genetic | Pathway causality | Small disc, notochordal cells |
| Rabbit puncture | MRI and injection feasibility | Induced injury |
| Dog spontaneous | Natural degeneration | Veterinary phenotype |
| Sheep/goat | Scale and implant mechanics | Quadrupedal load |
| Organ culture | Controlled dose/loading | No systemic context |
Reviews emphasize that no model reproduces human chronic pain, aging, size and endplate transport together (Daly 2016, PMID 27314030; Tang 2022, PMID 35812017).
Safety and governance¶
Potential harms include discitis, worsening pain, extrusion, nerve injury, ectopic bone/tissue, immune reaction and tumorigenicity. A case report of cauda equina with diffuse hyperplastic gliosis after unproven stem-cell injections shows why manufacturing and surveillance matter (Aoun 2019, PMID 31491761).
Minimum governance:
- regulated manufacturing and sterility;
- product identity, viability and potency;
- trial registration and protocol publication;
- independent safety monitoring;
- long-term registry follow-up;
- transparent funding/conflict reporting;
- no pay-to-participate therapeutic misconception.
Trial design¶
| Domain | Preferred design |
|---|---|
| Population | Moderate, symptomatic, coherent phenotype |
| Comparator | Saline/sham with puncture effects considered |
| Blinding | Patient, assessor and imaging core |
| Product | Full CMC characterization |
| Co-intervention | Standardized rehabilitation/medicines |
| Outcomes | Pain, ODI, participation, MRI, reintervention, harms |
| Timing | Early symptom plus ≥2–5-year structure/safety |
| Analysis | Responder, mean, missing-data sensitivity |
Evidence deepening: discriminating findings (2026-08-30)¶
The added evidence below was selected to change interpretation, not merely increase citation count. Each result is kept within its studied phenotype and design.
| Evidence | Quantified or mechanistic finding | Consequence for interpretation |
|---|---|---|
| The Safety and Effectiveness of Orthobiologic Injections for Discogenic Chronic Low Back Pain: A Multicenter Prospective, Crossover, Randomized Controlled Trial with 12 Months Follow-up (Navani 2024, PMID 38285032) | A 40-person multicenter randomized crossover trial compared saline trigger-point injection, intradiscal platelet-rich plasma and bone-marrow concentrate. | Small arms and crossover make durability and comparative efficacy uncertain. |
| Mesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain: A Systematic Review of Clinical Studies (Vadalà 2025, PMID 41508590) | A systematic review of 10 clinical studies included 736 participants (470 treated, 266 controls), with mean follow-up 21.6 months. | Product, dose, cell source and control heterogeneity preclude a generic stem-cell class effect. |
| Effectiveness of intradiscal platelet rich plasma for discogenic low back pain without Modic changes: A randomized controlled trial (Schepers 2022, PMID 39238810) | A randomized trial compared 1 mL intradiscal platelet-rich plasma with saline plus cefazolin and followed pain, RMDQ and SF-12 for one year. | The control formulation and Modic-negative eligibility are central to interpretation. |
| Efficacy of intervertebral disc regeneration with stem cells - a systematic review and meta-analysis of animal controlled trials (Wang 2015, PMID 25796605) | An animal meta-analysis included 22 controlled studies, nine randomized. | Preclinical structural improvement is hypothesis support, not a clinical efficacy estimate. |
| Potential Use of Extracellular Vesicles in the Treatment of Intervertebral Disc Degeneration (Li 2024, PMID 37930732) | An extracellular-vesicle meta-analysis pooled 19 animal studies involving 218 animals and reported improvements across MRI, height, apoptosis and histology outcomes. | All pooled endpoints remain preclinical and vulnerable to model and publication bias. |
| Clinical-transcriptomic classification of lumbar disc degeneration enhanced by machine learning (Jin 2025, PMID 40883814) | Transcriptomic profiling of 122 tissues from 108 patients proposed four molecular subtypes involving collagenesis, ossification, impaired chondrogenesis and fibrosis. | Molecular stratification could prevent biologic dilution, but requires prospective assay validation. |
Controversy carried forward¶
These additions narrow several claims but do not create a diagnostic gold standard. Where an imaging, molecular or treatment-response signal conflicts with sham-controlled, longitudinal or population evidence, the conflict is retained as a selection and transportability problem rather than resolved by vote.
Open questions¶
- Which baseline endplate and metabolic conditions permit cell survival and matrix synthesis? (Urban 2007, PMID 17260404)
- Do disc progenitor-cell results replicate independently with durable biomechanical benefit? (Gornet 2024, PMID 38925869)
- Are MSC benefits mediated by engraftment, paracrine signaling or contextual effects? (Vadalà 2021, PMID 34376495)
- What paired structural and clinical endpoint should define regeneration? (Schneider 2022, PMID 34352363)
- How can rare late harms be detected before broad commercialization? (Aoun 2019, PMID 31491761)
Related pages¶
- Cellular and molecular degeneration — targets.
- Disc anatomy and biomechanics — delivery environment.
- Injections and ablative procedures — procedural evidence.
- Biomarkers — response markers.
- Clinical trials landscape — registered studies.
- Outcomes and measurement — regeneration endpoints.
References¶
- Gornet MF, Beall DP, Davis TT, et al. Allogeneic Disc Progenitor Cells Safely Increase Disc Volume and Improve Pain, Disability, and Quality of Life in Patients With Lumbar Disc Degeneration-Results of an FDA-Approved Biologic Therapy Randomized Clinical Trial. International journal of spine surgery. 2024;18(3):237-248. PMID 38925869
- Noriega DC, Ardura F, Hernández-Ramajo R, et al. Intervertebral Disc Repair by Allogeneic Mesenchymal Bone Marrow Cells: A Randomized Controlled Trial. Transplantation. 2017;101(8):1945-1951. PMID 27661661
- Pers YM, Soler-Rich R, Vadalà G, et al. Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study). Annals of the rheumatic diseases. 2024;83(11):1572-1583. PMID 39393844
- Schneider BJ, Hunt C, Conger A, et al. The effectiveness of intradiscal biologic treatments for discogenic low back pain: a systematic review. The spine journal : official journal of the North American Spine Society. 2022;22(2):226-237. PMID 34352363
- Urban JP, Winlove CP. Pathophysiology of the intervertebral disc and the challenges for MRI. Journal of magnetic resonance imaging : JMRI. 2007;25(2):419-32. PMID 17260404
- Kadow T, Sowa G, Vo N, et al. Molecular basis of intervertebral disc degeneration and herniations: what are the important translational questions? Clinical orthopaedics and related research. 2015;473(6):1903-12. PMID 25024024
- Amirdelfan K, Bae H, McJunkin T, et al. Allogeneic mesenchymal precursor cells treatment for chronic low back pain associated with degenerative disc disease: a prospective randomized, placebo-controlled 36-month study of safety and efficacy. The spine journal : official journal of the North American Spine Society. 2021;21(2):212-230. PMID 33045417
- Vadalà G, Russo F, Lavazza C, et al. Intradiscal Mesenchymal Stromal Cell Therapy for the Treatment of Low Back Pain Due to Moderate-to-Advanced Multilevel Disc Degeneration: A Preliminary Report of a Double-Blind, Phase IIB Randomized Clinical Trial (DREAM Study). JOR spine. 2025;8(2):e70086. PMID 40462867
- Beall DP, Bae HW, DePalma MJ, et al. Efficacy and safety of allogeneic mesenchymal precursor cells with and without hyaluronic acid for treatment of chronic low back pain: a prospective, randomized, double blind, concurrent-controlled 36-month study. The spine journal : official journal of the North American Spine Society. 2025;25(9):1997-2013. PMID 40174800
- Vadalà G, Ambrosio L, Russo F, et al. Stem Cells and Intervertebral Disc Regeneration Overview-What They Can and Can't Do. International journal of spine surgery. 2021;15(s1):40-53. PMID 34376495
- Ekram S, Khalid S, Salim A, et al. Regulating the fate of stem cells for regenerating the intervertebral disc degeneration. World journal of stem cells. 2021;13(12):1881-1904. PMID 35069988
- Kumar H, Ha DH, Lee EJ, et al. Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study. Stem cell research & therapy. 2017;8(1):262. PMID 29141662
- Manchikanti L, Knezevic E, Knezevic NN, et al. Effectiveness of Intradiscal Regenerative Medicine Therapies for Long-Term Relief of Chronic Low Back Pain: A Systematic Review and Meta-Analysis. Pain physician. 2024;27(10):E995-E1032. PMID 39688822
- Hirase T, Jack Ii RA, Sochacki KR, et al. Systemic Review: Is an Intradiscal Injection of Platelet-Rich Plasma for Lumbar Disc Degeneration Effective? Cureus. 2020;12(6):e8831. PMID 32607308
- Akeda K, Ohishi K, Takegami N, et al. Platelet-Rich Plasma Releasate versus Corticosteroid for the Treatment of Discogenic Low Back Pain: A Double-Blind Randomized Controlled Trial. Journal of clinical medicine. 2022;11(2). PMID 35053999
- Hirase T, Jack RA, Sochacki KR, et al. Systematic Review: Is Intradiscal Injection of Bone Marrow Concentrate for Lumbar Disc Degeneration Effective? Cureus. 2020;12(7):e9045. PMID 32782864
- Ufondu W, Robinson CL, Hussain N, et al. Intradiscal Autologous Biologics for the Treatment of Chronic Discogenic Low Back Pain. Current pain and headache reports. 2024;28(11):1079-1095. PMID 39017984
- Rider SM, Mizuno S, Kang JD. Molecular Mechanisms of Intervertebral Disc Degeneration. Spine surgery and related research. 2019;3(1):1-11. PMID 31435545
- Zhang HJ, Liao HY, Bai DY, et al. MAPK /ERK signaling pathway: A potential target for the treatment of intervertebral disc degeneration. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2021;143:112170. PMID 34536759
- Wang C, Wang WJ, Yan YG, et al. MicroRNAs: New players in intervertebral disc degeneration. Clinica chimica acta; international journal of clinical chemistry. 2015;450:333-41. PMID 26368266
- Ran R, Liao HY, Wang ZQ, et al. Mechanisms and functions of long noncoding RNAs in intervertebral disc degeneration. Pathology, research and practice. 2022;235:153959. PMID 35653923
- Zhang J, Wang Z, Chen S, et al. From molecular regulation to tissue repair: hydrogels in the fight against intervertebral disc degeneration. Annals of medicine. 2025;57(1):2572310. PMID 41084298
- Nie G, Liu W, Zeng F, et al. Tissue engineering strategies for treating intervertebral disc degeneration. Frontiers in bioengineering and biotechnology. 2025;13:1582189. PMID 40727644
- Muftuler LT, Jarman JP, Yu HJ, et al. Association between intervertebral disc degeneration and endplate perfusion studied by DCE-MRI. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2015;24(4):679-85. PMID 25421547
- Daly C, Ghosh P, Jenkin G, et al. A Review of Animal Models of Intervertebral Disc Degeneration: Pathophysiology, Regeneration, and Translation to the Clinic. BioMed research international. 2016;2016:5952165. PMID 27314030
- Tang SN, Walter BA, Heimann MK, et al. In vivo Mouse Intervertebral Disc Degeneration Models and Their Utility as Translational Models of Clinical Discogenic Back Pain: A Comparative Review. Frontiers in pain research (Lausanne, Switzerland). 2022;3:894651. PMID 35812017
- Aoun SG, Peinado Reyes V, El Ahmadieh TY, et al. Stem cell injections for axial back pain: a systematic review of associated risks and complications with a case illustration of diffuse hyperplastic gliosis resulting in cauda equina syndrome. Journal of neurosurgery. Spine. 2019;31(6):906-913. PMID 31491761
- Navani A, Ambach M, Calodney A, Rosenthal R, Li G, Mahoney CB, et al. The Safety and Effectiveness of Orthobiologic Injections for Discogenic Chronic Low Back Pain: A Multicenter Prospective, Crossover, Randomized Controlled Trial with 12 Months Follow-up. Pain physician. 2024;27(1):E65-E77. PMID 38285032
- Vadalà G, Russo F, Papalia GF, Ambrosio L, Tucci M, Petrucci G, et al. Mesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain: A Systematic Review of Clinical Studies. Neurospine. 2025;22(4):998-1011. PMID 41508590
- Schepers MO, Groot D, Kleinjan EM, Pol MM, Mylenbusch H, Klopper-Kes AHJ, et al. Effectiveness of intradiscal platelet rich plasma for discogenic low back pain without Modic changes: A randomized controlled trial. Interventional pain medicine. 2022;1(1):100011. PMID 39238810
- Wang Z, Perez-Terzic CM, Smith J, Mauck WD, Shelerud RA, Maus TP, et al. Efficacy of intervertebral disc regeneration with stem cells - a systematic review and meta-analysis of animal controlled trials. Gene. 2015;564(1):1-8. PMID 25796605
- Li QW, Guo RC, Wu ZM, Shen CL. Potential Use of Extracellular Vesicles in the Treatment of Intervertebral Disc Degeneration. Tissue engineering. Part C, Methods. 2024;30(2):73-84. PMID 37930732
- Jin HJ, Lin P, Ma XY, Huang S, Zhang L, Hu O, et al. Clinical-transcriptomic classification of lumbar disc degeneration enhanced by machine learning. Military Medical Research. 2025;12(1):54. PMID 40883814